Karuna Therapeutics, Inc. KRTX NASDAQ

Karuna Therapeutics, Inc. (KRTX) reported total assets of $1.34B and total liabilities of $81.97M for fiscal year 2023, resulting in total equity of $1.25B.

The company held $1.26B in cash and short-term investments. Total debt stood at $16.69M, with net debt of $-169.14M. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 19.31, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.01, current ratio of 19.31 — balance sheet is strong
• MOAT (18/100) — Total assets $1.34B and equity $1.25B support the company's competitive scale
• VALUE (10/100) — Debt-to-Equity 0.01 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 27/100 with 1/7 criteria passed.

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

CYTK

Cytokinetics, Incorporated

$66.35

-0.55%

ISEE

IVERIC bio, Inc.

$39.95

+0.38%

APLS

Apellis Pharmaceuticals, Inc.

$40.85

+0.02%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

MRTX

Mirati Therapeutics, Inc.

$58.70

-0.17%

EWTX

Edgewise Therapeutics, Inc.

$33.16

-2.01%

DYN

Dyne Therapeutics, Inc.

$19.81

+4.26%